Stealth BioTherapeutics Corp MITO
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 23.54M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -6.40
- Beta
- 1.46
- Short ratio
- 1.77
- Inst. own
- 7.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 17, 2022
- 50-d avg
- 0.315554
- 200-d avg
- 0.368184
- 1y target
- 1.77
Key statistics
- Market cap
- 23.54M
- Enterprise value
- -14.39M
- Trailing P/E
- 0.00
- Forward P/E
- -6.40
- PEG ratio
- 0.10
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -0.924
- Beta
- 1.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -26.81M
- Total cash
- 47.13M
- Total debt
- 13.66M
- Return on equity
- 0.00%
- Shares outstanding
- 73.55M
- Short % of float
- 0.00%
- 50-day average
- 0.315554
- 200-day average
- 0.368184
Analyst view
Consensus: buy
- Target (low)
- 1.50
- Target (mean)
- 1.77
- Target (high)
- 2.05
Next earnings
Nov 17, 2022
Expected Nov 17, 2022. Consensus EPS estimate -0.02.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 17, 2022 | Sep 1, 2022 | -0.01 | — | — | — |
| Oct 6, 2022 | Jun 1, 2022 | -0.02 | — | — | — |
| May 18, 2022 | Mar 1, 2022 | -0.02 | — | — | — |
| Apr 7, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 11, 2021 | Sep 1, 2021 | -0.02 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | -0.02 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 23, 2022 | HC Wainwright & Co. | main | — | Buy |
| Jul 1, 2021 | Maxim Group | init | — | Buy |
| Apr 3, 2020 | Nomura | main | — | Buy |
| Apr 2, 2020 | HC Wainwright & Co. | up | Neutral | Buy |
| Dec 23, 2019 | H.C. Wainwright | down | Buy | Neutral |
| Sep 27, 2019 | Cantor Fitzgerald | init | — | Overweight |
About Stealth BioTherapeutics Corp
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Cayman Islands
- Website
- stealthbt.com
News
- FGR accelerates USA expansion & defence sector exposure with strategic acquisition of MITO® Material Solutions
- Stealth BioTherapeutics Announces FDA Accelerated Approval of FORZINITY™ (elamipretide HCl), the First Therapy for Progressive and Life-limiting Ultra-rare Genetic Disease Barth Syndrome
- STEALTH BIOTHERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME
- US FDA asks Stealth BioTherapeutics to resubmit application for rare genetic condition therapy
- FDA delays decision on Stealth BioTherapeutics' rare genetic disorder drug
- Stealth BioTherapeutics Announces PDUFA Action Date Extension for Elamipretide to Treat Patients with Barth Syndrome
- STEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION
- Stealth BioTherapeutics to Present at JMP Citizens Life Sciences Conference
- STEALTH BIOTHERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME
- Stealth BioTherapeutics to Present at the Baird 2023 Biotech Discovery Series
Your note
Sign in to keep a note on MITO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.59% | 435,516 | 139.37K | Sep 29, 2022 |
| Brown Brothers Harriman & Co | 0.24% | 174,999 | 56.00K | Sep 29, 2022 |
| Renaissance Technologies, LLC | 0.13% | 96,944 | 31.02K | Sep 29, 2022 |
| Geode Capital Management, LLC | 0.07% | 48,791 | 15.61K | Sep 29, 2022 |
| Boothbay Fund Management, LLC | 0.06% | 43,790 | 14.01K | Sep 29, 2022 |
| Susquehanna International Group, LLP | 0.04% | 30,991 | 9.92K | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.07% | 48,791 | 15.61K | Aug 30, 2022 |